The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
| ||||||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Revolution Medicines Inc | COM | 76155X100 | 17,242 | 685,011 | SH | SOLE | 685,011 | 0 | 0 | ||
| RAPT Therapeutics Inc | COM | 75382E109 | 5,341 | 145,401 | SH | SOLE | 145,401 | 0 | 0 | ||
| NGM Biopharmaceuticals Inc | COM | 62921N105 | 23,004 | 1,298,908 | SH | SOLE | 1,298,908 | 0 | 0 | ||
| Nurix Therapeutics Inc | COM | 67080M103 | 9,470 | 327,123 | SH | SOLE | 327,123 | 0 | 0 | ||